- The FDA has granted Orphan Drug Designation to Relief Therapeutics Holding AG's RLFTF for RLF-100 (aviptadil), an inhaled formulation, for sarcoidosis.
- RLF-100 is a synthetic form of vasoactive intestinal peptide.
- Sarcoidosis is a rare disease in which the inflammatory process involves the alveoli (air sacs), small bronchi, and small blood vessels.
- RLF-100 is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.
- Price Action: RLFTF shares closed at $0.24 on Monday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapFDAGeneralBriefsOrphan Drug DesignationSarcoidosis
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
